Georgian Health Minister Mikheil Sarjveladze met with parents of children with Type 1 Diabetes and medical professionals to review proposed amendments to the insulin supply programme. These changes will see treatment with NovoRapid replaced by Apidra, a rapidly acting insulin produced by the French pharmaceutical company Sanofi Aventis.

“Endocrinologists affirm that both NovoRapid and Apidra are high-quality medicines, and with active medical supervision, switching from one to the other will be safe for patients,” stated Mikheil Sarjveladze.

According to the Minister, Apidra is readily available in Georgia, and no supply issues are anticipated. He also mentioned that negotiations are ongoing to ensure that Novo Nordisk, the manufacturer of NovoRapid, fulfils its commitments and supplies the medication in the near future.